Breaking News

Tweet TWEET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. -- AMAG

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of
               Investors of AMAG Pharmaceuticals, Inc. -- AMAG

PR Newswire

NEW YORK, Sept. 25, 2013

NEW YORK, Sept. 25, 2013 /PRNewswire/ --Pomerantz Grossman Hufford Dahlstrom
& Gross LLP is investigating claims on behalf of investors of AMAG
Pharmaceuticals, Inc. ("AMAG" or the "Company")(NASDAQ: AMAG). Such investors
are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or
888-476-6529, ext. 237.

The investigation concerns whether AMAG and certain of its officers and/or
directors have violated Sections 10(b) and 20(a) of the Securities Exchange
Act of 1934. On December 21, 2012, AMAG submitted to the U.S. Food and Drug
Administration (the "FDA") a supplemental New Drug Application (the "sNDA")
under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Feraheme
(ferumoxytol) Injection, 510 mg. The sNDA sought approval for a broader
indication for Feraheme for the treatment of iron deficiency anemia in adult
patients who have failed or could not use oral iron. On September 23, 2013,
the Company received a notification from the FDA stating that, as part of its
ongoing review of the Company's sNDA, the FDA has identified deficiencies that
preclude discussion of labeling and postmarketing requirements/commitments by
September 23, 2013, a target date previously communicated by the FDA in a
letter dated March 5, 2013. On September 25, 2013 the Company announced in an
Securities and Exchange Commission Form 8-K filing, information regarding the
FDA notification received on September 23, 2013.

On this news, shares of AMAG fell $3.09 per share to more than 11.81% on
intraday trading to a price of $23.07 on September 25, 2013.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida,
is acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the Pomerantz Firm
pioneered the field of securities class actions. Today, more than 70 years
later, the Pomerantz Firm continues in the tradition he established, fighting
for the rights of the victims of securities fraud, breaches of fiduciary duty,
and corporate misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP
rswilloughby@pomlaw.com

SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP

Website: http://www.pomerantzlaw.com
 
Press spacebar to pause and continue. Press esc to stop.